|
Name: Daridorexant [(S)-2-(5-chloro-4-methyl-1H benzo[d]imidazol-2-yl)-2- methylpyrrolidin-1-yl](5-methoxy-2- (2H-1,2,3-triazol-2- yl)phenyl)methanone
Type: Hypnotic
AKA: QUVIVIQ
![Daridorexant [(S)-2-(5-chloro-4-methyl-1H benzo[d]imidazol-2-yl)-2- methylpyrrolidin-1-yl](5-methoxy-2- (2H-1,2,3-triazol-2- yl)phenyl)methanone image](https://grammasearch.com/dev/v2/aiimages/daridorexant_%5B%28s%29-2-%285-chloro-4-methyl-1h_benzo%5Bd%5Dimidazol-2-yl%29-2-_methylpyrrolidin-1-yl%5D%285-methoxy-2-_%282h-1%2C2%2C3-triazol-2-_yl%29phenyl%29methanone.png)
|
|
II. Natural Derivative
Synthetic substance, no natural derivative
 |
|
III. Chemical Profile (IUPAC name)
![Daridorexant [(S)-2-(5-chloro-4-methyl-1H benzo[d]imidazol-2-yl)-2- methylpyrrolidin-1-yl](5-methoxy-2- (2H-1,2,3-triazol-2- yl)phenyl)methanone image](/dev/v2/pages/pubchem_images/121775102.png)
|
|
IV. History
Daridorexant, developed in the 2020s, is a dual orexin receptor antagonist used in the treatment of insomnia. It represents a new class of sleep medications aimed at improving sleep quality by targeting orexin receptors in the brain.
|
|
V. Legal Information
Daridorexant, a medication used for sleep disorders, is regulated as a pharmaceutical agent. Its status reflects its use in managing sleep-related conditions and preventing misuse.
US Federal Schedule - IV
Schedule IV drugs, substances, or chemicals are defined as drugs with a low potential for abuse and low risk of dependence. Some examples of Schedule IV drugs are: Xanax, Soma, Darvon, Darvocet, Valium, Ativan, Talwin, Ambien, Tramadol.
Key US Federal Policies:
Controlled Substances Act. Public Law: Public Law 91-513 (text can be found on GovInfo) (https://www.dea.gov/drug-information/csa). Date enacted: October 27, 1970.
|
|
VI. Physical Effects
Daridorexant is a medication used to treat insomnia. As a downer, it promotes sleep and relaxation. Short-term effects include improved sleep quality, while long-term use is generally safe with minimal risks. Overdose risks are minimal but may include excessive sedation. Safe dosing is typically guided by a healthcare provider. Recent research focuses on its effectiveness for sleep disorders.  |
|
VII. Psychological Effects
Daridorexant, a dual orexin receptor antagonist, influences sleep and wakefulness. Immediate effects include improved sleep quality and reduced insomnia, with effects lasting up to 24 hours. Long-term use is generally safe but may lead to residual daytime drowsiness or mood changes. Research focuses on its efficacy in treating insomnia and potential for cognitive or mood disturbances.
 |
|
VIII. Culture
Daridorexant is a novel dual orexin receptor antagonist used for insomnia, classifying it as a downer. Short-term use promotes sleep and improves sleep quality, while long-term use can lead to dependency and tolerance. Overdose risks include severe sedation and potential respiratory depression. Safe dosages are typically prescribed by medical professionals, usually around 50 mg. Recent research highlights its efficacy in improving sleep without significant dependence risks. Physical effects include sedation, improved sleep, and potential for drowsiness the next day.
 |